In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Coherus Biosciences (CHRS – Research Report), with a price target of $30.00. The company's shares closed last Monday at $9.38, close to its 52-week low of $9.01. According to TipRanks.com, Syed is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -16.0% and a 34.2% success rate. Syed covers the Healthcare sector, focusing on stocks such as Atara Biotherapeutics, Assembly Biosciences, and Unity Biotechnology. Currently, the analyst consensus on Coherus Biosciences is a Strong Buy with an average price target of $23.58.
https://www.tipranks.com/news/blurbs/mizuho-securities-thinks-coherus-biosciences-stock-is-going-to-recover-5?utm_source=advfn.com&utm_medium=referral
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Coherus BioSciences Charts.
Coherus BioSciences (NASDAQ:CHRS)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Coherus BioSciences Charts.